Original Scientific Articles

Download PDF (2.84 MB)

Journal of Structural Heart Disease, February 2018, Volume 4, Issue 1:1-8
DOI: 10.12945/j.jshd.2018.035.17

Transcatheter Pulmonary Valve Replacement: The Venus P valve-Current Status

Wail Alkashkari, MD1, Jamilah AlRahimi, MD1, Saad Albugami, MD1, Qi-Ling Cao, MD2, Ziyad M. Hijazi, MD, MPH2,3

1 Department of Cardiology, King Saud Bin Abdulaziz University For Health Science and King Faisal Cardiac Center, Jeddah, Saudi Arabia
2 Sidra Cardiac Program, Sidra Medical & Research Center, Doha, Qatar
3 Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States


There is growing appreciation for the long-term adverse impact of right-sided dysfunction of the pulmonary valve in patients with congenital heart disease. Although pulmonary valve stenosis or regurgitation is often tolerated over the short and intermediate terms, the long-term consequences are numerous and include, but are not limited to, right-sided heart failure, arrhythmias, and sudden cardiac death. Surgical right ventricular outflow tract (RVOT) interventions have been performed for many decades as an initial therapy, but comorbidities associated with repeated surgeries are a concern. Transcatheter pulmonary valve replacement is safe, effective, and performed at an increasing number of centers around the world. It offers an alternative to traditional surgical techniques and may potentially alter the decision-making process whereby valvular replacement is performed prior to the development of long-term sequelae of RVOT dysfunction. However, only ~15% of potential patients with RVOT dysfunction are suitable for currently approved implantable valves (i.e., Melody valve from Medtronic and Edwards Sapien valves from Edwards Lifesciences). These two valve systems are designed and approved for patients with a conduit or bioprosthetic valve between the right ventricle and pulmonary artery, and they exclude most patients who undergo transannular patch repair techniques. The Venus P-valve (Venus Medtech, Shanghai, China) is a recently developed self-expanding transcatheter heart valve designed to adapt to a dilated RVOT and in such it provide patients with a percutaneous interventional option after transannular patch repair.


Download the article PDF (2.84 MB)

Download the full issue PDF (22.18 MB)

Mobile-ready Flipbook

View the full issue as a flipbook (Desktop and Mobile-ready)

Cite this article as: Alkashkari W, AlRahimi J, Albugami S, Cao Q, Hijazi ZM. Transcatheter Pulmonary Valve Replacement: The Venus P valve-Current Status. Structural Heart Disease 2018;4(1):1-8. DOI: 10.12945/j.jshd.2018.035.17

You must be registered and logged in to leave comments.

There have been no comments posted yet

All comments will be screened and reviewed before posting. Statements, opinions, and results of studies published in Journal of Structural Heart Disease are those of the authors and do not reflect the policy or position of The Journal and Science International and the Editorial Board and provides no warranty as to their accuracy or reliability. Material is copyrighted and owned by Science International and cannot be used without expressed permission.